查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
遺傳性血管性水腫市場：按藥物類別、給藥途徑、分銷渠道和地區 - 規模、份額、前景和機會分析，2022-2030
市場調查報告書
商品編碼
1110121

遺傳性血管性水腫市場：按藥物類別、給藥途徑、分銷渠道和地區 - 規模、份額、前景和機會分析，2022-2030

Hereditary Angioedema Market, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 175 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

遺傳性血管性水腫 (HAE) 的特徵是由常染色體顯性基因突變引起的急性皮膚和黏膜水腫。目前的治療方法包括靜脈注射、皮下注射和口服 HAE 藥物。這種疾病會導致腫脹，尤其是面部和呼吸道腫脹，以及腹部痙攣。氣道腫脹會導致阻塞，這可能是一種非常嚴重的並發症。這些症狀是由於某些蛋白質的缺乏或功能障礙導致的，這些蛋白質有助於保持液體流過非常小的血管（毛細血管）。這種疾病的嚴重程度在受影響的個體之間差異很大。皮膚腫脹會導致疼痛、殘疾和毀容，但通常不是危險的和暫時的。世界過敏組織 (WAO) 制定了使用不同類別藥物的指南，包括酯□抑製劑和激□釋放□抑製劑，這些藥物被批准用於治療遺傳性血管性水腫。 HAE 可能由 C1NH 基因（也稱為 SERPING1 基因）或 F12 基因中的基因改變（致病變異）引起。也有原因不明的情況。

市場動態

主要參與者將加入戰略聯盟和收購，以開發和擴展其遺傳性血管性水腫 (HAE) 產品組合，並加快各自的管道以加快產品交付速度。我們正在招聘。例如，2018年1月，設計和開髮用於遺傳性血管性水腫（HAE）和骨化性纖維發育不良（FOP）等罕見疾病的小分子藥物的BIOCRYST PHARMACEUTICALS, INC.與Biopharmaceutical公司Idera Pharmaceuticals合併，創建了一個新的罕見病。疾病公司。兩家公司的合併將創建一個全面且可持續的罕見病專業，利用集體技能、內部專業知識和綜合資產開發一系列罕見病的治療方法，包括預計將出現的生物技術公司的遺傳性血管性水腫。

本研究的主要特點

  • 它對全球遺傳性血管性水腫市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。
  • 解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
  • 該研究還提供了有關市場驅動因素、抑制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
  • 基於公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數的全球遺傳性血管性水腫市場主要參與者的概況。
  • 本研究涵蓋的主要公司包括 CSL Behring、武田製藥有限公司、Pharming、BIOCRYST PHARMACEUTICALS, INC.、Ionis Pharmaceuticals, Inc.、Attune Pharmaceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum Biotechnologies, Inc.、 KalVista Pharmaceuticals、CENTOGENE N.V.和賽諾菲
  • 本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。獎品
  • 全球遺傳性血管性水腫市場報告面向行業內的各種利益相關者，包括投資者和供應商、產品製造商、分銷商、新進入者和財務分析師。
  • 利益相關者可以通過用於分析全球遺傳性血管性水腫市場的各種策略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第2章市場展望

  • 舉報內容
    • 市場定義和範圍
  • 執行摘要
    • 市場快照：按藥物類別
    • 按管理途徑劃分的市場概況
    • 市場快照：按分銷渠道
    • 市場概況：按地區劃分
  • 連貫的機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

  • 市場動態
    • 驅動程序
    • 限制因素
    • 市場機會
  • 主要亮點
  • 管道分析
  • 監管準則
  • 流行病學

第 4 章全球遺傳性血管性水腫市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • 對供需的影響
  • COVID-19 的流行病學
  • COVID-19 對整個醫療保健市場的影響

第 5 章全球遺傳性血管性水腫市場：按藥物類別，2017-2030 年

  • C1酯□抑製劑
  • 激□釋放□抑製劑
  • 緩激□受體
  • 減少雄激素
  • 其他

第 6 章按管理途徑劃分的全球遺傳性血管性水腫市場：2017-2030 年

  • 皮下給藥
  • 靜脈給藥
  • 口服給藥

第 7 章。按分銷渠道劃分的全球遺傳性血管性水腫市場：2017-2030 年

  • 醫院藥房
  • 零售藥房
  • 電子商務

第 8 章全球遺傳性血管性水腫市場：2017-2030 年各地區

  • 北美
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地區
  • 歐洲
  • 英國
  • 德國
  • 意大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 東盟
  • 澳大利亞
  • 韓國
  • 其他亞太地區
  • 中東
  • 海合會
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第 9 章競爭格局

  • CSL Behring
  • Takeda Pharmaceutical Company Limited.
  • Pharming
  • BIOCRYST PHARMACEUTICALS, INC.
  • Ionis Pharmaceuticals, Inc.
  • Attune Pharmaceuticals
  • Arrowhead Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc.
  • KalVista Pharmaceuticals
  • CENTOGENE N.V.
  • Sanofi

第10章 章節

  • 調查手法
  • 關於出版社
簡介目錄
Product Code: CMI1292

Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes swelling particularly of the face and airways and abdominal cramping. Swelling of the airway may lead to obstruction, a potentially very serious complication. These symptoms develop as the result of deficiency or improper functioning of certain proteins that help to maintain the normal flow of fluids through very small blood vessels (capillaries). The severity of the disease varies greatly among affected individuals. Skin swelling can cause pain, dysfunction, and disfigurement, although it is generally not dangerous and is temporary. The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema. HAE may be caused by genetic changes (pathogenic variants) in the C1NH gene (also called the SERPING1 gene) or in the F12 gene. In some cases, the cause is not known.

Market Dynamics

Key players are adopting strategic collaborations and acquisitions for development and expansion of the hereditary angioedema (HAE) portfolio and to accelerate respective pipelines for faster delivery of products. For instance, In January 2018, BIOCRYST PHARMACEUTICALS, INC., a company that designs and develops small molecule medicines for rare diseases such as hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP), and Idera Pharmaceuticals, a clinical-stage biopharmaceutical company, merged to create a new rare-disease company. The combination of two companies is expected to capitalize on the collective skills sets, internal expertise and combined assets to create a comprehensive, sustainable rare disease-focused biotechnology company developing treatments for various rare diseases including hereditary angioedema.

Key features of the study:

  • This report provides in-depth analysis of the global hereditary angioedema market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hereditary angioedema market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include CSL Behring, Takeda Pharmaceutical Company Limited., Pharming, BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, CENTOGENE N.V., and Sanofi
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market

Detailed Segmentation:

  • Global Hereditary Angioedema Market, By Drug Class:
    • C1 Esterase Inhibitor
    • Kallikrein Inhibitor
    • Bradykinin Receptor
    • Attenuated Androgens
    • Others
  • Global Hereditary Angioedema Market, By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
  • Global Hereditary Angioedema Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • e-Commerce
  • Global Hereditary Angioedema Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • CSL Behring
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Takeda Pharmaceutical Company Limited.
    • Pharming
    • BIOCRYST PHARMACEUTICALS, INC.
    • Ionis Pharmaceuticals, Inc.
    • Attune Pharmaceuticals
    • Arrowhead Pharmaceuticals, Inc.
    • Adverum Biotechnologies, Inc.
    • KalVista Pharmaceuticals
    • CENTOGENE N.V.
    • Sanofi

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Key Highlights
  • Pipeline Analysis
  • Regulatory Guidelines
  • Epidemiology

4. Global Hereditary Angioedema Market - Impact of Coronavirus (Covid-19) Pandemic

  • Impact on Supply and Demand
  • COVID-19 Epidemiology
  • COVID-19 Impact on overall healthcare market

5. Global Hereditary Angioedema Market, By Drug Class, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • C1 Esterase Inhibitor
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Kallikrein Inhibitor
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Bradykinin Receptor
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Attenuated Androgens
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Hereditary Angioedema Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Subcutaneous
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Intravenous
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Hereditary Angioedema Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • e-Commerce
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Hereditary Angioedema Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • UK
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • CSL Behring
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Takeda Pharmaceutical Company Limited.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pharming
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • BIOCRYST PHARMACEUTICALS, INC.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ionis Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Attune Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Arrowhead Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Adverum Biotechnologies, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • KalVista Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CENTOGENE N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Section

  • Research Methodology
  • About Us